Neurotech Industry 2016-2017 Report: Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets

  • ID: 4372584
  • Report
  • 650 pages
  • NeuroInsights
1 of 3

Now in its 12th year, The Neurotechnology Industry 2016-2017 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.

The report includes detailed information on products in development globally for over 20 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.

  • More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
  • Pipelines and market analysis for 20 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
  • Top neurotech investors, venture capital firms, and venture capital trends
  • Neurotech IPOs, M&A, Partnering and Licensing deals and public neurotech stock performance
  • Analysis of biological basis, current treatment options, and emerging therapeutic strategies
  • Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
  • Global and US market size, worldwide revenues for each indication
  • Extensive discussion of specific technological, demographic, regulatory and intellectual property trends
Note: Product cover images may vary from those shown
2 of 3

1: Executive Summary

The Brain Industry Revealed      
    Cell Therapies   

Investment Risks and Opportunities
    Translating Neuroscience into Neurotech      
    The Neurotech Market Opportunity       

Key Industry Facts and Findings            

2: Trends and Drivers
Converging Technology Drivers          
    Crossing the Blood Brain Barrier     
Demographic Drivers      
    More People Living Longer     
Social Drivers     
    The Lifestyle Improvement Market             
Economic Drivers      
    Global Economic Burden of Brain-Related Illness      
    Rising Health Care Costs      
Research Funding       
    US Government Research Funding       
    Stem Cell Funding      
    International Government Research Funding      
    Foundations Focus on the Brain       
Intellectual Property Trends     
    Global Intellectual Property Protection      
    Patent Expirations      

Neurotech Merger and Acquisition Activity (2005-Q2,2016) 

3: Neuropharmaceutical Sector

Neuropharmaceutical Sector Overview     
    Trends in Neuropharmaceuticals      

Neuropharmaceutical Partnering and Licensing
      Partnering and Licensing Personnel
      Partnering and Licensing Deals 2004-Q2,2016
Neurology Markets and Pipelines       
    Alzheimer’s Disease (AD)      
    AAMI and MCI     

    Epilepsy and Seizure Disorders  
    Huntington's disease   
    Multiple Sclerosis      
    Parkinson’s Disease      
    Sleep Disorders      
         Restless Legs Syndrome      
    Traumatic Brain Injury
Psychiatry Markets and Pipelines      
    Anxiety Disorders      
    Attention Disorders      
    Depressive Disorders      
         Bipolar Disorder       
         Cognitive Impairment Associated with Schizophrenia      
Sensory Markets and Pipelines      
    Retinal Disorders
4: Stem Cells and Neuroregeneration

Defining Stem Cell Markets and Players      
    Drug Discovery Tools      
    Stem Cell Banking      
Stem Cell Approaches      
    The Science of Transplantion      
    Controlling Immune Rejection and Infection      
    Sources and Harvesting of Stem Cells       
        Embronic Stem Cells     
        Fetal Stem Cells      
        Adult Stem Cells     
        Stimulation of Endogenous Stem Cells      
    Stem Cells Scientific Hurdles     
Markets and Treatments in Development      
    Alzheimer’s Disease       
    Amyotrophic Lateral Sclerosis (ALS)     
    Hearing Loss     
    Huntington’s Disease (HD)   
    Multiple Sclerosis (MS)     
    Parkinson’s Disease     
    Retinal Disorders      
    Spinal Cord Injury (SCI)     
    Other CNS Diseases  

 5: Neurodevice Sector
Neurodevice Sector Overview       
    Neurodevice Markets      
    Regulatory Process in the US
    Regulatory Process in the EU     
    Neurodevice Sector Trends       
    Investment by Major Device companies
    Neurodevice M&A Activity (2005-Q2, 2016)

Neuroprosthetic Devices      
    Cochlear Implants       
    Retinal Implants       
    Motor Prostheses and Brain Computer Interfaces     

Neuromodulation Devices       
    Neuromodulation Device Clinial Trials and Recent Approvals       
    Deep Brain Stimulation      
         Essential Tremor       
         Parkinson’s Disease       
         Primary Dystonia       
         Severe Obsessive Compulsive Disorder       
         Treatment-Resistant Depression       
         Traumatic Brain Injury and Stroke       
    Transcranial Magnetic Stimulation (TMS)       
         Treatment Resistant Depression      

    Transcranial Electrical Stimulation (TES)     
         Transcranial Direct Current Stimulation (tDCS)

         Transcranial Alternating Current Stimulation (tACS)      
         Transcranial Random Noise Stimulation (tRNS)
    Focused Ultrasonic Modulation  

    Spinal Cord Stimulation (SCS)      
         Chronic and Neuropathic Pain       
         Spinal Cord Injury       
    Vagus Nerve Stimulation (VNS)       
         Treatment-Resistant Depression       
    Peripheral Stimulation       
         Assisted Breathing
         Fecal Incontinence       
         Foot Drop       
         Neuropathic Pain       
         Restless Legs Syndrome       
         Sleep Apnea       
         Urinary Conditions       
    Gastric Modulation and Obesity      

Neurosurgical devices       
    Radiosurgical Devices       
    Neurosurgical Navigation and Equipment       
         Image Guided Navigation (IGN)      
         Intraoperative Magnetic Resonance Imaging (iMRI)      
         Automated Surgical Systems       
         Brain Monitoring       
         Temperature Control Systems       
    Neurovascular Intervention        
         Ischemic Stroke       
             Catheters, Stents and Perfusion devices
             Retrieval and Protection devices
             Ultrasound Thrombolysis
         Hemorrhagic Stroke  
              Liquid Embolics
    Attention Deficit Disorder      
    Cognition and Aging      
    Stress and Emotional Wellbeing      
    Addiction and Obesity

Therapeutic NeuroGaming

6: Neurodiagnostics Sector

Neurodiagnostic Sector Overview      
    FDA Approval and Reimbursement of Diagnostics             
Neuroimaging Technologies      
    Computed Tomography (CT)      
    Magnetic Resonance Imaging (MRI)      
    Nuclear Medicine Imaging (PET, SPECT)      
    Electro-encephalography (EEG)      
    Magneto-encephalography (MEG)      
In Vitro Diagnostics      
    In Vitro Diagnostics Regulatory Landscape      
    Emerging Diagnostics for Alzheimer’s Disease
    Emerging Diagnostics for TBI      
    Genetic Testing and Pharmacogenomics     
    Protein Biomarker Assays      
    Pattern Recognition in Diagnostics      
    Emerging Diagnostics for Psychiatry 
    Emerging Diagnostics for Autism           
    Diagnostic Software       

7: Private Neurotechnology Investment

Private Investment in Neurotechnology      
    Venture Capital Investment Trends      
    Neurotech Venture Capital Investment      
         Investing in Neuropharmaceuticals      
         Investing in Stem Cells and Neuroregeneration     
         Investing in Neurodevices      
         Investing in Neurodiagnostics      
         Private Company Financings, 2015
         Top financings 2004-2015
         Leading Neurotech Investors
         Leading Venture Capital Firms      

8: Public Neurotechnology Investment

Investing in Public Neurotech Companies      
    Neurotech Stock Universe      
Neurotech Initial Public Offerings      
NeuroInsights Neurotech Index      

9: Neurotechnology Research Centers

Leading Neurotechnology Research Centers      
    University of California, San Francisco (UCSF)      
    University of California, Los Angeles (UCLA)      
    University of California, San Diego (UCSD)      
    Stanford University      
    Massachusetts Institute of Technology (MIT)      
    Columbia University      
    Washington University, St. Louis      
    University College London (UCL)      
    Karolinska Institutet, Stockholm      
    RIKEN Brain Science Institute, Japan      
Places to Watch      
    National Brain Research Centre (NBRC), India      
    Neurosciences Victoria, Australia (NSV)      
    Univeristy of Helsinki, Finland

10: Leading Neurotechnology Regions

The Global Neurotech Economy      
Nexus Ranking and Methodology      
Established Neurotech Nexus
Emerging Neurotech Nexus  
Nascent Neurotech Nexus
Conclusions and Policy Recommendations      

11: Company Profiles
Neuropharmaceutical & Cell Therapy Companies: Private      
Neuropharmaceutical & Cell Therapy Companies: Public     
Neurodevice Companies: Private      
Neurodevice Companies: Public      
Neurodiagnostic Companies: Private      
Neurodiagnostic Companies: Public    

12: Index

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown